Free Delivery Over $100
|
|
|||
|
||||
OverviewThis book presents the state-of-the-art for development of fusion proteins, demonstrates current concepts, describes multiple applications, and discusses typical challenges linked to these molecules. It overviews the multitude of possibilities to design novel protein drugs while balancing between proven concepts and new ideas that have not reached the clinic yet. The book is structured into three larger parts. First general issues and concepts are discussed before in the second part examples on the three categories (time, toxicity, and targeting) are presented. Finally, novel concepts and the rising class of multispecifc antibodies are described. Together, the chapters combine the success stories of marketed drugs with the dynamic preclinical and clinical research into novel drugs addressing unmet medical needs. Full Product DetailsAuthor: SR SchmidtPublisher: John Wiley & Sons Inc Imprint: John Wiley & Sons Inc Dimensions: Width: 17.10cm , Height: 1.50cm , Length: 24.60cm Weight: 0.984kg ISBN: 9781118354599ISBN 10: 1118354591 Pages: 672 Publication Date: 13 February 2013 Audience: Professional and scholarly , Professional & Vocational Format: Digital Publisher's Status: Active Availability: Not yet available  This item is yet to be released. You can pre-order this item and we will dispatch it to you upon its release. Table of ContentsReviewsOverall, this book is a bona fide companion for newcomers, as well as for experts in the pharmaceutical industry, in biotechnology or universities with affiliations to industry and medicine. (mAbs, 15 April 2015) Author InformationSTEFAN R. SCHMIDT, PhD , is Vice President for Downstream Processing at Rentschler Biotechnology. Previously, he served as CSO at ERA Biotech and Associate Director for Protein Science at AstraZeneca. Dr. Schmidt has chaired many international conferences and written several original articles, reviews, and book chapters. Tab Content 6Author Website:Countries AvailableAll regions |
||||
